Travere Therapeutics Inc (NASDAQ: TVTX) is -24.14% lower on its value in year-to-date trading and has touched a low of $5.12 and a high of $19.54 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TVTX stock was last observed hovering at around $6.75 in the last trading session, with the day’s gains setting it 0.07%.
Currently trading at $6.82, the stock is 13.56% and -2.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.23 million and changing 1.04% at the moment leaves the stock -24.84% off its SMA200. TVTX registered -59.26% loss for a year compared to 6-month gain of 2.71%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -0.58% loss in the last 1 month and extending the period to 3 months gives it a -17.63%, and is 13.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.03% over the week and 6.69% over the month.
Travere Therapeutics Inc (TVTX) has around 380 employees, a market worth around $519.21M and $183.22M in sales. Profit margin for the company is -211.29%. Distance from 52-week low is 33.20% and -65.10% from its 52-week high. The company has generated returns on investments over the last 12 months (-81.84%).
The EPS is expected to shrink by -118.46% this year
The shares outstanding are 75.37M, and float is at 75.06M with Short Float at 15.72%.
Travere Therapeutics Inc (TVTX) Insider Activity
The most recent transaction is an insider sale by Cline Christopher R., the company’s CHIEF FINANCIAL OFFICER. SEC filings show that Cline Christopher R. sold 54 shares of the company’s common stock on Apr 11 ’24 at a price of $6.74 per share for a total of $364.0. Following the sale, the insider now owns 70849.0 shares.
Travere Therapeutics Inc disclosed in a document filed with the SEC on Feb 01 ’24 that Dube Eric M (CHIEF EXECUTIVE OFFICER) sold a total of 19,122 shares of the company’s common stock. The trade occurred on Feb 01 ’24 and was made at $8.70 per share for $0.17 million. Following the transaction, the insider now directly holds 0.35 million shares of the TVTX stock.
Still, SEC filings show that on Feb 01 ’24, REED ELIZABETH E (SVP, GC & CORPORATE SECRETARY) disposed off 4,764 shares at an average price of $8.71 for $41495.0. The insider now directly holds 76,270 shares of Travere Therapeutics Inc (TVTX).
